GERN
Geron CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.90
P/S
5.78
EV/EBITDA
-23.71
DCF Value
$-7.80
FCF Yield
-10.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.0%
Operating Margin
-29.3%
Net Margin
-46.7%
ROE
-34.2%
ROA
-15.0%
ROIC
-11.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $48.0M | $-31.1M | $-0.05 |
| FY 2025 | $183.9M | $-85.8M | $-0.13 |
| Q3 2025 | $47.2M | $-18.4M | $-0.03 |
| Q2 2025 | $49.0M | $-16.4M | $-0.02 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.67
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.